Summary:
- Royalty Pharma and Teva Pharmaceutical Industries have entered into an agreement to accelerate the development of a potential treatment for vitiligo, a skin condition that causes white patches to appear on the skin.
- The agreement allows Royalty Pharma to provide funding to Teva for the continued development of the treatment, which is currently in the clinical trial phase.
- This collaboration aims to bring a new treatment option to the market more quickly, which could benefit those living with vitiligo and improve their quality of life.